Karbinal ER FDA Approval History
FDA Approved: Yes (First approved March 28, 2013)
Brand name: Karbinal ER
Generic name: carbinoxamine
Dosage form: Extended-Release Oral Suspension
Company: Tris Pharma, Inc.
Treatment for: Conjunctivitis, Allergic, Allergic Reactions, Allergic Rhinitis, Allergic Urticaria
Karbinal ER (carbinoxamine maleate) extended-release oral suspension is an H1 receptor antagonist indicated for the symptomatic treatment of seasonal and perennial allergic rhinitis.
Development Timeline for Karbinal ER
|Apr 3, 2013||FDA Approves Tris Pharma's New Drug Application for Karbinal ER|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.